# 32nd ANNUAL NORTH AMERICAN CF CONFERENCE
## NACFC 2018 Abstract Categories

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>USE THIS CATEGORY IF YOUR ABSTRACT IS ABOUT:</th>
</tr>
</thead>
</table>
| AIRWAYS PHYSIOLOGY, PATHOPHYSIOLOGY & AIRWAYS DEFENSE | • Cellular responses to infection  
• Endogenous antimicrobial defenses  
• Epithelial ion & fluid transport (including channels & regulation)  
• Inherent abnormalities in airway and immune cells in CF  
• Mechanisms of fibrosis and repair  
• Related therapies  
• Mucus secretion & clearance  
• Tissue function including smooth muscle and interstitium |
| CFTR | • Biogenesis & trafficking  
• Expression of CFTR  
• Pharmacology  
• Properties |
| EDUCATION | • Case management  
• CFRD  
• Education of healthcare professionals about CF  
• New complications  
• Newly diagnosed  
• Patient & family education (inpatient as well as outpatient)  
• Standards of care |
| ENDOCRINE/BONE | • Bone disease including (sex hormones, pregnancy hormones, growth hormones & fertility)  
• Diabetes |
| EPIDEMIOLOGY & NEWBORN SCREENING | • Epidemiological & newborn screening  
(screening studies, including newborn screening) |
| GENETICS | • CF-related gene expression  
  • Counseling issues  
  • Ethical/ legal/social issues  
  • Genotype/phenotype relationship of diagnostic measures (including sweat testing, NPD measurement)  
  • Heritable variations  
  • Modifier genes |
|---|---|
| GI/NUTRITION | • Appetite stimulants  
  • BMI, ideal body weight, macro- & micronutrients  
  • Body composition  
  • Energy expenditure & intake  
  • Fatty acids & essential fatty acid profile  
  • Feeding behavior issues  
  • Gastrointestinal disease (including GER, DIOS, etc.)  
  • Liver disease  
  • Nutrition failure  
  • Nutritional assessment & treatment  
  • Pancreatic enzyme supplementation  
  • Pancreatitis & pancreas-related issues  
  • Parenteral nutrition  
  • Tube feeding  
  • Use of complementary/ alternative supplements  
  • Vitamin/mineral supplementation |
| INFECTION/MICROBIOLOGY | • Antibiotics (pharmacokinetics/treatment)  
  • Host microbe interaction  
  • Infection control  
  • Microbe physiology & gene expression  
  • Microbial community profiling  
  • Molecular epidemiology  
  • Pathogenesis of infection  
  • Systems biology of infection |
| MODEL SYSTEMS | • Animal models  
  • Cellular models  
  • In vitro systems |
| NEW THERAPIES, BIOMARKERS & OUTCOME MEASURES | • CFTR modulator and other pharmacological treatments  
• Gene therapy/editing/stem cell-based intervention  
• Preclinical and clinical outcome measures such as lung imaging, respiratory function, biomarkers |
| NURSING ISSUES | • Access to care  
• Advocacy  
• Clinic processes  
• Home care  
• Inpatient and/or outpatient nursing care  
• Insurance issues/third-party liaison  
• Nursing role on CF team  
• Palliative care  
• Patient self-management  
• Research coordination/management  
• Staff development  
• Team coordination  
• Telephone management/triage  
• The role of advanced practice nurses- (including management issues and clinical care)  
• Transition programs  
• Venous access devices |
| PHYSICAL & RESPIRATORY THERAPY | • Airway clearance techniques  
• Exercise  
• Musculoskeletal & neuromuscular problems/therapies  
• Urinary & bowel incontinence |
<table>
<thead>
<tr>
<th>Category</th>
<th>Topics</th>
</tr>
</thead>
</table>
| PSYCHOSOCIAL/BEHAVIORAL          | • Adaptation of patients & families to diagnosis & medical interventions  
                                 | • Adherence                                                           
                                 | • Complementary/alternative therapies (except supplements) assessment  
                                 | • Emotional/social/behavioral/ sexual development                     
                                 | • End-of-life issues                                                   
                                 | • Family functioning, parenting & marital issues                       
                                 | • Life expectations                                                    
                                 | • Measurement & use of quality of life tools                           
                                 | • Pain management                                                      
                                 | • Patient/family/caregiver interaction & communication                
                                 | • Problems of dealing with chronic disease                             
                                 | • Psychosocial impact of transition to adult care                      
                                 | • Support system development                                           
                                 | • Treatment of psychological/psychiatric disorders (including depression, anxiety, etc.) |
| PULMONARY                        | • Aerosol delivery systems (including new ones)                         
                                 | • Evaluation (including PFTs, BAL, bronchoscopy, radiological assessment, etc.) 
                                 | • Pathology                                                            
                                 | • Pulmonary exacerbations/ treatment                                  
                                 | • Pulmonary physiology                                                 |
| QUALITY IMPROVEMENT              | • QI (including projects/efforts/tools & patient & family involvement) |
| TRANSPLANTATION                  | • Medical, psychosocial & epidemiological issues related to organ transplantation in CF |
| UTILIZATION AND COVERAGE         | • Access to care                                                       
                                 | • Advocacy                                                             
                                 | • Case management                                                      
                                 | • Cost & payment                                                       
                                 | • Cost effectiveness analysis                                          
                                 | • Health and healthcare disparities                                   
                                 | • Health care utilization                                              
                                 | • Insurance issues/ third-party liaison                                |